Literature DB >> 6127390

Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant.

T Terasaki, T Iga, Y Sugiyama, M Hanano.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127390     DOI: 10.1111/j.2042-7158.1982.tb04804.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  13 in total

1.  Physiological pharmacokinetic model of adriamycin delivered via magnetic albumin microspheres in the rat.

Authors:  J M Gallo; C T Hung; P K Gupta; D G Perrier
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

2.  Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs in rats.

Authors:  N Yata; T Toyoda; T Murakami; A Nishiura; Y Higashi
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

3.  Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.

Authors:  Tanaya R Vaidya; Hardik Mody; Yesenia L Franco; Ashley Brown; Sihem Ait-Oudhia
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

4.  A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

Authors:  Guohua An; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-27       Impact factor: 4.009

Review 5.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

6.  Theoretical consideration of drug distribution kinetics in a noneliminating organ: comparison between a "homogeneous (well-stirred)" model and "nonhomogeneous (tube)" model.

Authors:  T Terasaki; Y Sugiyama; T Iga; Y Sawada; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

7.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

Authors:  P Gunvén; N O Theve; C Peterson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Mechanistic approaches to volume of distribution predictions: understanding the processes.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

10.  Implications of pharmacokinetic modeling in risk assessment analysis.

Authors:  R J Lutz; R L Dedrick
Journal:  Environ Health Perspect       Date:  1987-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.